Altimmune, Inc. ALT
2.12 USD +0.08 (+3.92%)
At closeNov 4, 2026, 7:10 PM EST
2.11 -0.01 -0.27%
After hours · Nov 4, 7:10 PM ET
2.03 Day range 2.15
1.99 52-week range 6.44
- YTD
- -41.27%
- 1 year
- -43.62%
- Market cap
- 412.38M
- Revenue (ttm)
- 52.00K
- EPS (ttm)
- -0.76
- Shares out
- 71.12M
- Forward P/E
- -5.14
- YTD return
- -41.27%
- 1-year return
- -43.62%
- Volume
- 3.47M
- Avg volume
- 3.92M
- Open
- 2.10
- Previous close
- 2.04
- Day's range
- 2.03 – 2.15
- 52-week range
- 1.99 – 6.44
- Beta
- 0.07
- Analysts
- Buy
- Price target
- 22.86 (+978.2%)
5D -0.03 (-1.40%)
Key statistics
- Enterprise value
- 449.17M
- PEG ratio
- 0.00
- Price / sales
- 10326.74
- Price / book
- 4.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -98.60%
- Free cash flow
- -45.63M
- Total cash
- 139.38M
- Total debt
- 1.77M
- Return on equity
- -72.96%
- Short % of float
- 33.04%
- 50-day average
- 7.91
- 200-day average
- 7.41
Analyst view
Consensus: buy
Buy
Price target (mean) 22.86 +978.2% upside
Now 2.12
- Target (low)
- 12.00
- Target (mean)
- 22.86
- Target (high)
- 28.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy3
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.24.
Financials — quick view
ALT Revenue — quarterly 0
ALT Net income — quarterly -22.82M
ALT EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.36 | -0.32 | +0.04 | +11.11% |
| Aug 8, 2024 | Jun 1, 2024 | -0.34 | -0.35 | -0.01 | -2.94% |
| May 9, 2024 | Mar 1, 2024 | -0.36 | -0.34 | +0.02 | +5.56% |
| Mar 27, 2024 | Dec 1, 2023 | -0.35 | -0.33 | +0.02 | +5.71% |
| Nov 7, 2023 | Sep 1, 2023 | -0.40 | -0.39 | +0.01 | +2.50% |
| Aug 10, 2023 | Jun 1, 2023 | -0.44 | -0.32 | +0.12 | +27.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | UBS | init | — | Buy |
| Aug 12, 2024 | B. Riley Securities | reit | Buy | Buy |
| Jun 25, 2024 | B. Riley Securities | reit | Buy | Buy |
| Jun 21, 2024 | Piper Sandler | main | Overweight | Overweight |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- altimmune.com
News
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution 
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and 
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium 
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) 
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026 
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 
Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets 
Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise 
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
Your note
Sign in to keep a note on ALT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DRUTZ DAVID J | Director | Sale | Aug 18, 2024 | 0 |
| EISENSTADT RICHARD I | Chief Financial Officer | Stock Award(Grant) | Jan 30, 2024 | 45,012 |
| GARG VIPIN K. | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 1, 2024 | 292,028 |
| HARRIS MATTHEW SCOTT | Officer | Stock Award(Grant) | Jul 30, 2024 | 55,119 |
| JORDT RAYMOND M | Officer | Stock Award(Grant) | Jul 30, 2024 | 14,660 |
| ROBERTS M SCOT | Officer | Stock Award(Grant) | Jul 30, 2024 | 43,325 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.69% | 5,466,094 | 41.27M | Sep 29, 2024 |
| Vanguard Group Inc | 7.01% | 4,983,858 | 37.63M | Sep 29, 2024 |
| Ameriprise Financial, Inc. | 5.45% | 3,876,044 | 29.26M | Sep 29, 2024 |
| State Street Corporation | 4.80% | 3,413,827 | 25.77M | Sep 29, 2024 |
| Tang Capital Management, LLC | 3.87% | 2,750,000 | 20.76M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.35% | 1,668,004 | 12.59M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.63% | 2,584,274 | 19.51M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.57% | 1,830,974 | 13.82M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.52% | 1,790,759 | 13.52M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.54% | 1,098,135 | 8.29M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.02% | 727,869 | 5.50M | Aug 30, 2024 |
| Fidelity Strategic Advisors Small-Mid Cap Fund | 0.57% | 406,082 | 3.07M | Jul 30, 2024 |